Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Headache, Heart rate, Immunisation, Myocarditis
Clinical narrative: myocarditis/chest pain, arrhythmia, shortness of breath, heartrate to the 160's,; headache; dizziness; Pfizer BTC vaccine (purple formula,12 and older) booster dose; This is a spontaneous report received from contactable reporter(s) (Other HCP) from medical information team. The reporter is the patient.  A 38 year-old female patient received bnt162b2 (BNT162B2), administered in arm right, administration date 13Dec2021 16:00 (Lot number: FE3594) at the age of 38 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Psoriasis", start date: 2013 (ongoing). Concomitant medication(s) included: CLOBETASOL taken for psoriasis, start date: 2013 (ongoing); VYVANSE, start date: 2015 (ongoing). Vaccination history included: Bnt162b2 (Dose 1, Lot: EK5730 , Received in the left arm), administration date: 05Jan2021, when the patient was 37 years old, for COVID-19 Immunization, reaction(s): "Achy", "Tired"; Bnt162b2 (Dose 2: , Lot: EL3248 , Received in the left arm), administration date: 22Jan2021, when the patient was 37 years old, for COVID-19 Immunization, reaction(s): "Achy", "Tired". The following information was reported: IMMUNISATION (medically significant) with onset 13Dec2021 16:00, outcome "unknown", described as "Pfizer BTC vaccine (purple formula,12 and older) booster dose"; MYOCARDITIS (medically significant) with onset 14Dec2021 08:00, outcome "recovered" (19Dec2021), described as "myocarditis/chest pain, arrhythmia, shortness of breath, heartrate to the 160's,"; HEADACHE (medically significant) with onset 14Dec2021, outcome "recovered" (19Dec2021), described as "headache"; DIZZINESS (medically significant) with onset 14Dec2021, outcome "recovered" (19Dec2021), described as "dizziness". The events "myocarditis/chest pain, arrhythmia, shortness of breath, heartrate to the 160's,", "headache" and "dizziness" were evaluated at the emergency room visit. The patient underwent the following laboratory tests and procedures: heart rate: (14Dec2021) 160's, notes: heart rate to the 160's. Clinical course: The patient had no prior vaccinations (within 4 weeks) and no family medical history relevant to events. The patient used to take Adderall when she was child and switched to Vivance in 2015. The patient called and reported an adverse reaction that happened after the Covid-19 Vaccine booster dose for adults. The patient received the Pfizer BTC vaccine (purple formula,12 and older) booster dose on 13Dec2021. The symptoms only occurred with the booster dose; when she received her 1st and 2nd doses, she was only "achy and tired" that only lasted 12-24 hours. She received the vaccine (third dose), and she was having chest pain after the booster and that is why she went to the ER. Her PCP would not see her to do an EKG because she was having chest pain. She was sent to and ended up in the emergency department (ED). She thought she had myocarditis. The ED ruled out myocarditis. She was having heart rate elevation into the 160's, chest pain, shortness of breath, and arrhythmias. She had severe headache and dizziness when her heart rate elevated. She said that she had the Covid-19 booster on 13Dec2021 at 1600. Her chest pain started on 14Dec2021 at about 0800. Heart rate elevation started at around 0800 as well on 14Dec2021. Her heart rate situation was recorded on her phone because she has an Apple watch. Her shortness of breath (SOB) started at about noon. She stated that the shortness of breath was periodic and would accompany her heart rate elevations and arrhythmias. She said that it was obvious she had an arrhythmia because she would get dizzy when it would occur. No relevant tests done. The patient said that the ER physician said that he has seen plenty of people with the same kind of adverse events in the ER strictly from the Pfizer Booster.; Sender's Comments: The contributory role of the product bnt162b2 (COMIRNATY)  to reported events myocarditis, headache and dizziness is possible. This case will be reassessed upon receipt of follow-up information.